Edwards Lifesciences Corp., a medical research company specializing in heart disease and critical care monitoring, has captured the attention of several institutional investors like &Koshinski Asset Management. The company has experienced increased demand for its products, thanks to its focus on patient-centric medical innovations in four areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. Edwards Lifesciences stock has seen fluctuations over the past year with a low of $67.13 and a high of $131.10. It closed at $83.45 on Wednesday, marking its second consecutive day of gains, and showed a mix of trading performance with Dow Jones and S&P500. Edwards Lifesciences' success can be attributed to its strong financial performance as evidenced by its P/E ratio of 34.10 and PEG ratio of 4.82 with a beta value of 1.02 which reflects its volatility compared to the broader market. With a market cap of $50.43 billion, a debt-to-equity ratio of 0.10, a current ratio of 3.03, and a quick ratio of 2.17, the company is in a strong financial position, making it an attractive long-term investment possibility for stakeholders in the healthcare industry or potential investors seeking stable financial providers offering promising results for their clientele.